Stay updated on Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.

Latest updates to the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. No visible content changes are indicated.SummaryDifference0.0%

- Check69 days agoChange DetectedAdded Gastric Cancer to the related topics section and included Genetic and Rare Diseases Information Center as a resources reference.SummaryDifference0.1%

- Check75 days agoChange DetectedSite updated to revision v3.4.2; a government funding/status notice previously shown (v3.4.1) has been removed.SummaryDifference0.3%

- Check83 days agoChange DetectedAdded a government funding lapse notice with updated operating status for the NIH Clinical Center and updated the site version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.